Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Spesolimab in Healthy Chinese Subjects
NCT04390568Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of spesolimab in generalized pustular psoriasis (GPP) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Spesolimab in Plasma Over the Time Interval From 0 Extrapolated to Infinity up to 4200 hours and Maximum Measured Concentration of Spesolimab in Plasma up to 4200 hours. Started May 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT04390568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390568.